

Poster Sessions

Day 1: September 24 (Tuesday) 2024

Room 2 (The Club Fuji C) 17:50-18:50

Poster Session 1: Systemic Therapy [Early Career] (1)

Chair: Dr. Naoki Morimoto (Japan)

P-01 10019

An Effective Prognostic Risk Model Related to Fatty Acid Metabolism in Hepatocellular Carcinoma

Dr. Xiaobin Li (China)

P-02 10042

Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma

Dr. Risako Kohya (Japan)

P-03 10065

The Importance of Assessing Energy Malnutrition in Atezolizumab/Bevacizumab Therapy

Dr. Maho Egusa (Japan)

P-04 10114

Understanding the Disease Stage of Intermediate Stage Hepatocellular Carcinoma (HCC) - Analysis of Initial Treatment and Tumor Conditions

Dr. Teppei Akatsuka (Japan)

P-05 10117

Analysis of Immune-mediated Adverse Event Colitis Induced by Combination Therapy with Durvalumab and Tremelimumab for Advanced Hepatocellular Carcinoma

Dr. Makoto Fujjya (Japan)

P-06 10126

Pathophysiology of Immune Related Liver Injury from a Clinicopathological Perspective

Dr. Ryo Izai (Japan)

P-07 10150

Sorafenib Induced Stevens-Johnson Syndrome after Immune Checkpoint Inhibitor Treatment in a Patient of Hepatocellular Carcinoma

Dr. Kosuke Kojima (Japan)

Poster Session 2: Basic Research [Early Career]

Chair: Dr. Yasunari Nakamoto (Japan)

P-08 10012

Solanum Torvum Induces Ferroptosis to Suppress Hepatocellular Carcinoma through Suppression of GPX4 and Activation of HO-1

Dr. Hsiang-Chun Lai (Taiwan)

P-09 10018

Chai Qi Yi Gan Granule Restores Gut Microbial Balance and Modulates Lipid Metabolism to Suppress Hepatocellular Carcinoma

Dr. Xiaobin Li (China)

P-10 10066

Integrated Single-Cell and Bulk RNA Sequencing Reveals CCR2-High Neutrophils in Gr1+ Myeloid Lineages of CRLM Mice

Dr. Zijun Yan (China)

P-11 10133

Early Width of Dispersion of Monocytes Complexity (MO-WX) as a Discriminating Tool of Hepatocellular Carcinoma in Liver Cirrhotic: A Pilot Study of Novel Marker with Leukocytes Cell Population Data

Dr. Dwijo A Sindhughosa (Indonesia)

P-12 10153

Biflavonoid Derivatives as Potential CDK1 Inhibitors in Hepatocellular Carcinoma: Investigation via Virtual Screening and Molecular Interaction Analysis

Dr. Reny Rosalina (Indonesia)

P-13 10125

Withdrawn

P-14 10049

Dietary Elaidic Acids Promotes Malignant Behavior of HepG2 Cells via NF-kappaB Signaling Pathway

Dr. Xiao Hu (China)

Poster Session 3: Liver Cirrhosis and Portal Hypertension [Early Career]

Chair: Dr. Masanori Atsukawa (Japan)

P-15 10015

Association between Osteosarcopenia and Prognosis in Liver Cirrhosis Complicated with Portal Hypertension

Dr. Arisa Saito (Japan)

P-16 10017

Reasons for Liver Regeneration Failure, How to Save it?

Dr. Bowen Liu (China)

P-17 10050

Long-term L-carnitine Supplementation Suppresses Skeletal Muscle Mass Loss by Decreasing the Expression of Interleukin-6 in Patients with Hepatocellular Carcinoma

Dr. Yu Takeda (Japan)

P-18 10052

Effect of MAFLD Criteria on Postoperative Recurrence of NBNC-HCC

Dr. Yusuke Johira (Japan)

P-19 10092

Effectiveness of Multidisciplinary Inpatient Treatment with Personalized Diet and Exercise Therapy for Steatotic Liver Disease

Dr. Eriksson Yasuka (Japan)

P-20 10156

Virtual Screening of Resveratrol-derived Compounds for Targeting the TGF- β 1 Receptor in Liver Fibrosis

Dr. Rian Ka Praja (Indonesia)

P-21 10144

Mathematical Modelling for Investigating the Inconsistencies between Transient Elastography and Liver Biopsy Results in Assessing Liver Fibrosis in Patients with Chronic Viral Hepatitis

Dr. Prihantini Prihantini (Indonesia)

Poster Session 4: Case Report [Early Career] (1)

Chair: Dr. Kazuyoshi Ohkawa (Japan)

P-22 10051

A Resected Case of Hepatocellular Carcinoma with Paraneoplastic Syndrome

Dr. Mai Totsuka (Japan)

P-23 10056

A Case of Hepatic Leiomyosarcoma Diagnosed through Autopsy

Dr. Kensho Kubo (Japan)

P-24 10079

A Case of Hilar Bile Duct Carcinoma with Severe Eosinophilia

Dr. Terunao Iwanaga (Japan)

P-25 10109

A Case of Hepatic Reactive Lymphoid Hyperplasia Diagnosed by Post-RFA Biopsy Specimen

Dr. Masaki Kawabata (Japan)

P-26 10111

Cytokine Release Syndrome Caused by the Combination Immunotherapy for Advanced Hepatocellular Carcinoma

Dr. Sae Yumita (Japan)

Poster Session 5: Case Report [Early Career] (2)

Chair: Dr. Yoshiyuki Ueno (Japan)

P-27 10006

A Case of Hepatocellular Carcinoma that could be Radically Resected after Combined Therapy with Lenvatinib and TACE

Dr. Ryo Yano (Japan)

P-28 10035

A Case of Consciously Selected LEN-TACE for Unresectable HCC Combined with Acquired Thrombotic Thrombocytopenic Purpura

Dr. Tsuyoshi Fujioka (Japan)

P-29 10093

Hepatocellular Carcinoma with Long Complete Response after Liver and Lung Resections and Lenvatinib

Dr. Shohe Kobe (Japan)

P-30 10135

Anti-HCV Treatment Using Direct-acting Antivirals during Systemic Immunotherapy for Unresectable Hepatocellular Carcinoma may Contribute to Improving Long-term Prognosis: A Case Report

Dr. Wataru Ueno (Japan)

P-31 10148

A Case of Fatal Immune-Mediated Myocarditis Following Durvalumab and Tremelimumab Combination Therapy (DT) for Multiple Hepatocellular Carcinomas

Dr. Ryo Saito (Japan)

Poster Session 6: Systemic Therapy (1)

Chair: Dr. Toshifumi Tada (Japan)

P-32 10004

Impact of Atezolizumab + Bevacizumab Combination Therapy on Health-related Quality of Life and Relationship with Prognosis in Patients with Advanced Hepatocellular Carcinoma

Dr. Masako Shomura (Japan)

P-33 10038

Cytokine Analysis as a Predictive Biomarker of Response to Treatment with Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma

Dr. Satoshi Kobayashi (Japan)

P-34 10055

Pretreatment Predictors of Response to Combination Therapy with Atezolizumab/Bevacizumab in Advanced Stage Hepatocellular Carcinoma

Dr. Norikazu Tanabe (Japan)

P-35 10141

Clinical Significance of Oncological Resectability Criteria in Patients Treated with Atezolizumab and Bevacizumab

Dr. Yutaka Yasui (Japan)

P-36 10155

Outcomes of Atezolizumab Plus Bevacizumab (Atezo/Bev) Therapy for Hepatocellular Carcinoma (HCC) without Macroscopic Vascular Invasion (MVI) or Extrahepatic Spread (EHS) ~ Focus on Tumor Factors

Dr. Michihisa Moriguchi (Japan)

P-37 10161

CyTOF Reveals Platelet Subtype Changes Predicting the Efficacy of Combined Immunotherapy and Targeted Therapy in Liver Cancer

Dr. Junfeng Lu (China)

Poster Session 7: Systemic Therapy (2)

Chair: Dr. Hidenori Nagai (Japan)

P-38 10059

Predictive Factors for Objective Response Rate in Patients with Unresectable Hepatocellular Carcinoma Treated with Durvalumab plus Tremelimumab Therapy

Dr. Yuki Shirane (Japan)

P-39 10062

Efficacy and Safety of Durvalumab plus Tremelimumab for Advanced Hepatocellular Carcinoma with Esophageal Varices

Dr. Naoshi Odagiri (Japan)

P-40 10069

Effective Monitoring of Durvalumab plus Tremelimumab Therapy Using Tumor Marker

Dr. Issei Saeki (Japan)

P-41 10089

Efficacy and Safety of Immunotherapy for Real-World Elderly Patients with Unresectable Hepatocellular Carcinoma in Japan

Dr. Shun Kaneko (Japan)

P-42 10110

Treatment Efficacy in Durvalumab plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma with Previous Immune Check Point Inhibitor

Dr. Nami Mori (Japan)

Poster Session 8: Surgical Resection, Transplantation, and Local Therapy (1)

Chair: Dr. Hiroaki Nagano (Japan)

P-43 10007

Surgical Outcomes of Combined Hepatocellular-Cholangiocarcinoma in Comparison to Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: a Propensity-Score Matched Analysis

Dr. Hae Won Lee (Korea)

P-44 10030

Short- and Long-term Outcomes of Laparoscopic Liver Resection for Non-alcoholic Fatty Liver Disease-associated Hepatocellular Carcinoma

Dr. Yukihiro Watanabe (Japan)

P-45 10054

Significance of Repeated Laparoscopic Liver Resection for Recurrent HCC after Curative Treatment

Dr. Yuji Iimuro (Japan)

P-46 10057

Attenuation of Hepatic Ischemia-reperfusion Injury Associated with Liver Transplantation by Curcumin in Rodents via Anti-inflammatory Action

Dr. Ekta Yadav (India)

P-47 10082

Current Status of Tumor Ablation in Japan and the Japan Academy of Tumor Ablation (JATA)

Dr. Shuichiro Shiina (Japan)

P-127 10129

Efficacy of HAIC with 3D-CRT for Unresectable Advanced Hepatocellular Carcinoma Complicated by Major Vascular Tumor Thrombosis

Dr. Joji Tani (Japan)

Poster Session 9: Clinical Research of Liver Cancer (1)

Chair: Dr. Michiaki Unno (Japan)

P-48 10008

Clinical Significance of Biliary Invasion at Diagnosis in Barcelona Clinic Liver Cancer Stage B-C Hepatocellular Carcinoma: a Nationwide Cohort Analysis in South Korea

Dr. Sunmin Park (Korea)

P-49 10020

Clinical Characteristics and Prognosis of Hepatocellular Carcinoma Patients without Liver Fibrosis

Dr. Fujimasa Tada (Japan)

P-50 10046

Second-Line Treatment Strategy in Unresectable Hepatocellular Carcinoma after First-Line Atezolizumab Plus Bevacizumab

Dr. Kunihide Mohri (Japan)

P-51 10074

Influence of Gender Differences and Aging on the Clinical Background of Patients with Hepatocellular Carcinoma

Dr. Atsushi Hiraoka (Japan)

P-52 10088

Real World Data of Cabozantinib in Patients with Hepatocellular Carcinoma: Focusing on Dose Setting and Modification

Dr. Hironao Okubo (Japan)

P-53 10136

Comprehensive Analysis of Reaching Radiological Cancer-free Status in Advanced-stage Hepatocellular Carcinoma

Dr. Keisuke Koroki (Japan)

P-54 10152

Real-world Experience of Cabozantinib after Immunotherapy in Patients with Unresectable Hepatocellular Carcinoma

Dr. Kaoru Tsuchiya (Japan)

Poster Session 10: Liver Cirrhosis and Portal Hypertension

Chair: Dr. Keisuke Kakisaka (Japan)

P-55 10022

Hepatocellular Carcinoma is a Prognostic Factor in Patients Treated for Esophagogastric Varices

Dr. Akira Uchiyama (Japan)

P-56 10037

Subharmonic-Aided Pressure Estimation (SHAPE); A New Noninvasive Technique for Diagnosing Portal Hypertension

Dr. Yoshiko Nakamura (Japan)

P-57 10058

Enhancing Bioavailability of Furosemide for the Management of Portal Hypertension Using Self Nano Emulsifying Drug Delivery System

Dr. Pankajkumar Yadav (India)

P-58 10073

Significance of Neutrophil-to-lymphocyte Ratio in Bleeding after Endoscopic Treatment of Cirrhotic Patients with Esophageal Varices

Dr. Kazuto Takahashi (Japan)

P-59 10083

Regional Difference for Morbidity of Liver Cancer and Spread of Ultrasound Elastography in Japan: A Real-world Evidence Using National Database of Health Insurance Claims

Dr. Masahito Nakano (Japan)

P-60 10120

Efficacy and Safety of Avatrombopag

Dr. Rie Goka (Japan)

P-61 10143

The Diagnostic Ability of the Prediction for Hepatocarcinogenesis Using Non-invasive Scoring Systems Including VCTE and CAP in Patients with MASLD/MASH

Dr. Takashi Nishimura (Japan)

Poster Session 11: MASLD

Chair: Dr. Takumi Kawaguchi (Japan)

P-62 10011

Effects of SGLT2 Inhibitors on the Onset of Extrahepatic Cancer in Type 2 Diabetic Patients with MASLD: A Nationwide Database Study in Japan

Dr. Takumi Kawaguchi (Japan)

P-63 10090

Effect of MAFLD on Hepatocarcinogenesis in HBeAg-negative Patients with Undetectable HBV-DNA under NA Therapy: A Multicenter Study

Dr. Keisuke Amano (Japan)

P-64 10116

Modified Forms of Secondary Bile Acid Levels Could be Biomarkers of Hepatocellular Carcinoma Pathogenesis in MASLD Patients

Dr. Yoshimi Yukawa-Muto (Japan)

P-65 10122

Efficacy of Measuring Natural Killer-activating Receptor Ligands to Predict the Pathogenesis of Metabolic Dysfunction-associated Steatotic Liver Disease

Dr. Jun Arai (Japan)

Poster Session 12: Basic Research (1)

Chair: Dr. Naoshi Nishida (Japan)

P-66 10026

Can the Blood Coagulation Factor Von Willebrand Factor be a Predictor of Response to Atezolizumab plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma?

Dr. Naoki Nishimura (Japan)

P-67 10053

Interaction of PKR and 4.1R Promotes Anchorage-independent Growth of Hepatocellular Carcinoma

Dr. Yusuke Okujima (Japan)

P-68 10108

Hepatoma-derived Growth Factor as a Possible Therapeutic Target for Hepatocellular Carcinoma

Dr. Hirayuki Enomoto (Japan)

P-69 10160

Morphological Architectures of Patient-derived Hepatocellular Carcinoma Organoids with GSK3-beta Expression Dependent Variability According to Lenvatinib Resistance

Dr. Jun Yong Park (Korea)

P-70 10166

Role of Erastin in Intestinal Injury Following Perioperative Liver Transplantation via Ferroptosis in Animals

Dr. Deepika Singh (India)

Poster Session 13: Case Report (1)

Chair: Dr. Tomokazu Kawaoka (Japan)

P-71 10043

A Case of Child-Pugh C with Advanced HCC Treated by a Hepatologist

Dr. Shuntaro Obi (Japan)

P-72 10045

Atezolizumab and Bevacizumab following Stereotactic Body Radiotherapy for Two Patients with Unresectable Hepatocellular Carcinomas with Vp4/Vv3 and Vp3 Macrovascular Invasion

Dr. Satoshi Komiyama (Japan)

P-73 10060

A Case Study of Advanced Hepatocellular Carcinoma Treated with Radiotherapy and Chemotherapy

Dr. Hideo Yoshida (Japan)

P-74 10063

A Case of Hepatocellular Carcinoma with Vp4 Treated with Durvalumab plus Tremelimumab after Lenvatinib plus Hepatic Artery Infusion Chemotherapy

Dr. Mariko Nishioka (Japan)

P-75 10102

Curative Treatment of Two Hepatocellular Carcinoma Cases with Radiofrequency Ablation Following Atezolizumab Plus Bevacizumab

Dr. Kosuke Matsumoto (Japan)

P-76 10145

A Case of Vp4 Hepatocellular Carcinoma Successfully Treated with Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy (HAIC-RT) and Subsequent Molecular Targeted Therapy

Dr. Hirotoishi Ebinuma (Japan)

P-77 10158

A Case of a Hepatocellular Carcinoma Associated with Autoimmune Hepatitis with Atezolizumab and Bevacizumab Therapy

Dr. Kazuo Tsubura (Japan)

Poster Sessions

Day 2: September 25 (Wednesday) 2024

Room 2 (The Club Fuji C) 16:20-17:20

Poster Session 14: Systemic Therapy [Early Carrer] (2)

Chair: Dr. Teiji Kuzuya (Japan)

P-78 10014

Comparing Clinical Outcomes between PD-L1 and PD-1 Inhibitors Plus Anti-VEGF Antibody Combined with Hepatic Arterial Interventional Therapies in Unresectable HCC: A Single-center, Real-world Study

Dr. Yangxun Pan (China)

P-79 10080

The Efficacy and Safety of Durvalumab + Tremelimumab for Unresectable Hepatocellular Carcinoma

Dr. Aiko Tanaka (Japan)

P-80 10113

Exploring the Safety and Efficacy of Durvalumab Monotherapy for Advanced Hepatocellular Carcinoma Patients Ineligible for Combined Immunotherapy

Dr. Chihiro Miwa (Japan)

P-81 10123

Integrative Deep Learning Framework for Investigating the Role of Tumor-Associated Macrophages in Hepatocellular Carcinoma Metastasis Using Single-Cell Multi-Omics and Spatial Transcriptomics

Dr. Rifaldy Fajar (Indonesia)

P-82 10127

Re-positioning of Hepatic Arterial Infusion Chemotherapy in the Era of Systemic Therapy

Dr. Takahiro Tsuchiya (Japan)

P-83 10139

Significance of Two Patterns of ICI Rechallenge with STRIDE Therapy in Advanced Hepatocellular Carcinoma

Dr. Takuya Yonemoto (Japan)

P-84 10159

Real-World Outcomes of Durvalumab Plus Tremelimumab Combination Therapy (DT Therapy) in Unresectable Hepatocellular Carcinoma: Analysis by Treatment Line and Prognostic Factors

Dr. Naoki Uchihara (Japan)

Poster Session 15: Surgical Resection, Transplantation, and Local Therapy
[Early Career]

Chair: Dr. Mitsuo Shimada (Japan)

P-85 10013

Challenges and Scope in Deceased Donor Liver Transplantation in Bangladesh: The Dynamics of Ethics, Socio-culture and Religion

Dr. Md Ismail Gazi (Bangladesh)

P-86 10025

Influence of RFA on Liver Reserve Function in Child-Pugh B Patients with HCC within Milan Criteria

Dr. Ayaka Nakamura (Japan)

P-87 10040

Indocyanine Green Applied in Unresectable Hepatocellular Carcinoma after Neoadjuvant Combination Therapy

Dr. ManLuo (China)

P-88 10077

How Far Economics Analysis Does Matter: The Relation of Macroeconomic, Education, and Wealth with Liver Transplantation

Dr. Rosinta H.P. Purba (Indonesia)

P-89 10078

Epidemiology and Risk Factors Relating to Post-Liver Transplantation (LT) in Children

Dr. Lintong H. Simbolon (Indonesia)

P-90 10084

Outcome of Hepatectomy after Systemic Therapy in Hepatocellular Carcinoma: A Japanese Multi-Center Study

Dr. Norifumi Iseda (Japan)

P-91 10128

Efficacy and Safety of Superselective Transarterial Chemoembolization Combined with Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Single-Center Retrospective Cohort Study

Dr. Takuya Watanabe (Japan)

Poster Session 16: Hepatobiliary Malignancy [Early Career]

Chair: Dr. Manabu Morimoto (Japan)

P-92 10003

Targeting Ferroptosis with Polymerized Platinum (IV) Prodrugs Nanoparticles with Everolimus for Enhancing Therapeutic Efficacy on Cholangiocarcinoma

Dr. Yang Chen (China)

P-93 10010

Examination of Interactions Affecting Epithelial-mesenchymal Transition in Intrahepatic Colangiocarcinoma

Dr. Takahiro Haruna (Japan)

P-94 10031

Perioperative Outcomes of Robotic Radical Resection for Gallbladder Cancer: A Single-center Case Series

Dr. Ji-Min Dai (China)

P-95 10068

High-precision Genomic Analysis Using the Molecular Barcoding Method in Liquid Biopsy of Pancreaticobiliary Cancer

Dr. Miho Sakai (Japan)

P-96 10115

Effects of SGLT2 Inhibitors on Cholangiocarcinoma in Cell Lines and an Animal Model

Dr. Daisuke Minowa (Japan)

P-97 10131

Blood CGP Pave the Way for Genomic Therapy in Biliary Tract Cancer ?

Dr. Yoshiki Ogane (Japan)

P-98 10132

The Usefulness of Tissue CGP in Real-World Biliary Tract Cancer Treatment

Dr. Yu Sekine (Japan)

Poster Session 17: Viral Hepatitis [Early Carrer]

Chair: Dr. Masahito Shimizu (Japan)

P-99 10033

A Study on Hepatocellular Carcinoma and Intestinal Microflora in Patients with Chronic Hepatitis B

Dr. Yusuke Tanaka (Japan)

P-100 10034

Clinical Feature of Hepatocellular Carcinoma Patients with Overall Survival (10 Years or More)

Dr. Takuya Matsuda (Japan)

P-101 10036

Treatment Outcomes of Patients with Unresectable Hepatocellular Carcinoma: A Single Center Retrospective Cohort Study

Dr. Christmae M. Solon (Philippines)

P-102 10048

HBV preS1/HBsAg Ratio is a Predictive Marker for the Occurrence of Hepatocellular Carcinoma

Dr. Masanari Kosaka (Japan)

P-103 10157

Promising Antiviral siRNAs for Targeting NS4A and NS5A in Hepatitis C Virus Genotype 1

Dr. Rian Ka Praja (Indonesia)

P-104 10162

The Correlation between Interleukin-6 and the Progression of Chronic Hepatitis B

Dr. Mohamed S. Mohaboob Ali (Malaysia)

P-105 10142

An Advanced Predictive System Using Gradient Boosting Machines (GBM) to Forecast Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Virus Infection

Dr. Prihantini Prihantini (Indonesia)

Poster Session 18: Case Report [Early Career] (3)

Chair: Dr. Kazuhiro Nouse (Japan)

P-106 10103

A Case of Atezolizumab-Bevacizumab Combination Therapy with Good Long-Term Prognosis Despite Prolonged Bevacizumab Withdrawal

Dr. Fumiya Suzuki (Japan)

P-107 10134

A Case of Hepatocellular Carcinoma with Bone Metastasis Achieved Complete Response Using Stereotactic Radiotherapy and Lenvatinib, Following Anti-PD-L1 Antibody-induced Psoriasis-like Dermatitis

Dr. Chikako Nagao (Japan)

P-108 10146

A Case of Hepatocellular Carcinoma with Multiple Pulmonary Metastatic Recurrences at Distant Stage after Radical Cure

Dr. Akihiko Nishimura (Japan)

P-109 10147

Remarkable Response to Atezolizumab plus Bevacizumab Therapy after Pseudo-progression, Followed by Phenotypic Change in Conversion Surgery: A Unique Case of Hepatocellular Carcinoma

Dr. Midori Sawada (Japan)

P-110 10169

A Cholangiolocellular Carcinoma Case Showing Slow Tumor Growth and Marked Intratumoral Lymphocyte Infiltration, with a Favorable Outcome

Dr. Ayaka Gamo (Japan)

Poster Session 19: Systemic Therapy (3)

Chair: Dr. Hayato Hikita (Japan)

P-111 10001

Survey of Systemic Drug Therapy for Unresectable Hepatocellular Carcinoma in Non-designated Regional Cancer Treatment Hospital in Japan

Dr. Hidehiro Kamezaki (Japan)

P-112 10044

Hepatic Dysfunction in 879 ICI-treated Patients; Does Referral to a Hepatologist Improve OS?

Dr. Kaori Matsumoto (Japan)

P-113 10061

Atezolizumab plus Bevacizumab Shows PFS Benefit in mALBI Grade 2 HCC

Dr. Shunji Watanabe (Japan)

P-114 10075

Results of Atezolizumab Combined with Bevacizumab for Advanced Hepatocellular Carcinoma in Vietnamese Patients

Dr. Hang T. Hoang (Viet Nam)

P-115 10099

Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy

Dr. Masanori Inoue (Japan)

P-116 10107

A Retrospective Analysis of Liver Volume Decrease in Advanced Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab and Lenvatinib

Dr. Tomoharu Yamada (Japan)

P-117 10121

Diagnosis Triggers and Outcomes in Patients Treated with Atezolizumab/Bevacizumab as Initial Treatment for Hepatocellular Carcinoma

Dr. Teiji Kuzuya (Japan)

Poster Session 20: Systemic Therapy (4)

Chair: Dr. Tatehiro Kagawa (Japan)

P-118 10027

Systemic Therapy for Unresectable HCC Combination with TACE (Lenvatinib or Atezolizumab/Bevacizumab)

Dr. Ryu Sasaki (Japan)

P-119 10100

Efficacy of Lenvatinib + New FP Combination Therapy in the Treatment of Unresectable Advanced Hepatocellular Carcinoma

Dr. Susumu Maruta (Japan)

P-120 10124

Combining On-demand Locoregional Treatment for Drug-resistant Lesions during Atezolizumab and Bevacizumab Therapy in Unresectable Hepatocellular Carcinoma

Dr. Tasuku Nakabori (Japan)

P-121 10138

Effectiveness of Immune Checkpoint Inhibitor Therapy with Locoregional Therapy Versus ICI Alone in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis

Dr. Yasuhide Motoyoshi (Japan)

P-122 10149

Is Lenvatinib Resumption Necessary after Lenvatinib-TACE Combination Treatment ?

Dr. Rie Sugimoto (Japan)

P-123 10165

Effect of Radiofrequency Ablation on the Therapeutic Efficacy of Atezolizumab/Bevacizumab Combination Therapy

Dr. Masahiko Tameda (Japan)

Poster Session 21: Surgical Resection, Transplantation, and Local Therapy (2)

Chair: Dr. Shuntaro Obi (Japan)

P-124 10029

Carbon-ion Radiotherapy for Hepatocellular Carcinoma 4 cm or Larger

Dr. Tetsuro Isozaki (Japan)

P-125 10081

Ablation Training Program for Liver Tumors at Juntendo

Dr. Shuichiro Shiina (Japan)

P-126 10098

LI-RADS CT/MRI Radiation Treatment Response Assessment Version 2024: Evaluation after Transarterial Radioembolization for Hepatocellular Carcinoma

Dr. Sunyoung Lee (Korea)

P-128 10151

Clinical Outcomes with Stereotactic Body Radiation Therapy in Patients with Hepatocellular Carcinoma

Dr. Puja Sahai (India)

Poster Session 22: Clinical Research of Liver Cancer (2)

Chair: Dr. Hirayuki Enomoto (Japan)

P-129 10071

Efficacy of the GFAD Index as a New Indicator for the Early Diagnosis of Non-Viral Hepatocellular Carcinoma

Dr. Akiyo Ishiguro (Japan)

P-130 10087

The Association between the Prognoses and Systemic Chemotherapy According to the Oncological Conditions in Patients with Colorectal Liver Metastases

Dr. Nozomu Sakai (Japan)

P-131 10095

Quality of Life in Patients with Hepatobiliary Cancers

Dr. Asmin Valiyagath (India)

P-132 10097

Does Transcatheter Arterial Chemoembolization for Liver Metastasis in Neuroendocrine Tumors Reduce Hepatic Reserve?

Dr. Asako Nogami (Japan)

P-133 10101

Clinical Outcome of GCD Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Dr. Hiroki Inada (Japan)

P-134 10105

Etiological Transitions in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: a Single-center Study from an Institution Located in a District with a High Prevalence of Viral Hepatitis

Dr. Hirayuki Enomoto (Japan)

P-135 10140

Atezolizumab plus Bevacizumab for Combined Hepatocellular Cholangiocarcinoma

Dr. Tomoyuki Satake (Japan)

Poster Session 23: Viral Hepatitis

Chair: Dr. Norio Akuta (Japan)

P-136 10070

A Novel Hepatitis Delta virus (HDV) in Vitro Carcinogenesis Model

Dr. Shinya Sato (Japan)

P-137 10091

The Prognosis of Hemodialyzed Patients with Hepatitis C Treated by Direct Acting Antivirals

Dr. Hitoshi Takagi (Japan)

P-138 10094

Comprehensive RNA-seq Analysis of HCV-infected Cells and Specimens from Patients with Liver Cancer after HCV eradication to Elucidate Liver Carcinogenesis

Dr. Katsuya Nagaoka (Japan)

P-139 10096

Epidemiology of Liver Disease in Kerala: A Retrospective Study

Dr. Sabin Katpattil (India)

Poster Session 24: Basic Research (2)

Chair: Dr. Tsutomu Masaki (Japan)

P-140 10021

Oncolytic Activity of a Chimeric Influenza A Virus Carrying a Human CTLA4 Antibody in Hepatocellular Carcinoma

Dr. Penghui Yang (China)

P-141 10024

Cabozantinib Prevents the Progression of Metabolic Dysfunction-associated Steatohepatitis by Inhibiting the Activation of Hepatic Stellate Cell and Macrophage and Attenuating Angiogenic Activity

Dr. Takuya Matsuda (Japan)

P-142 10028

Extracellular Vesicles-mediated Mutant β -catenin Transfer from Hepatocyte Activates Hepatic Stellate Cells in Tumor Microenvironment

Dr. Yu Ota (Japan)

P-143 10032

Tumor-derived CCL15 Regulates RNA m6A Methylation in Cancer-associated Fibroblasts to Promote Hepatocellular Carcinoma Growth

Dr. Yueguo Li (China)

P-144 10112

A Near-infrared-modulated System Enabling Efficient Delivery of Glucose Derivative as a New Therapeutic Strategy for Liver Cancer

Dr. Sohji Nishina (Japan)

P-145 10164

Chemoprotective Effect of Crocetin-Dextrin Nano-formulation against N-diethylnitrosamine Induced Hepatocellular Carcinoma in Rats via Mitochondrial Apoptosis and PI3K/Akt/mTOR Signaling Pathways

Dr. Vikas Kumar (India)

P-146 10168

The Whole Genome and RNA Sequence Analysis on the Hepatocellular Carcinoma Derived from the Patients with Fontan-associated Liver Disease

Dr. Taiji Yamazoe (Japan)

Poster Session 25: Basic Research (3)

Chair: Dr. Makoto Chuma (Japan)

P-147 10009

Development of a Small Animal Model for Fatty Liver-related Hepatocarcinogenesis Research

Dr. Daiki Miki (Japan)

P-148 10039

Withdrawn

P-149 10047

Inhibitory Effects of Putrescine on Metabolic Dysfunction-associated Steatopatitis in Mice
Dr. Erdenetsogt Dungubat (Japan)

P-150 10119

Exploring the Link Between Mitochondrial ROS, Peroxiredoxin V, and Liver Fibrosis in Metabolic Associated Fatty Liver Disease

Dr. Hyun Ae Woo (Korea)

P-151 10167

Efalizumab Modulates HAT1 and Increases IL-9 to Induce Ferroptosis and CD8+ T Cell Immunological Activity in Hepatocellular Carcinoma

Dr. Manvendra Singh (India)

P-152 10170

Invasive Hepatic Stellate Cell Shapes Immunovascular Landscape of Hepatocellular Carcinoma

Dr. Michitaka Matsuda (Japan)

P-159 10171

Investigation of TEAD Inhibitor for Hepatocellular Carcinoma Treatment

Dr. Yoshinobu Saito (Japan)

Poster Session 26: Case Report (2)

Chair: Dr. Takahiro Yamazaki (Japan)

P-153 10023

Myositis Induced by an Immune Checkpoint Inhibitor in a Hepatocellular Carcinoma Patient with Primary Biliary Cirrhosis: A Case Report

Dr. Naoya Tsuzuki (Japan)

P-154 10067

A Case of Unresectable Hepatocellular Carcinoma Complicated by Cerebral Hemorrhage after Combined Therapy with Atezolizumab and Bevacizumab

Dr. Tamami Abe (Japan)

P-155 10072

A Case of Duodenal Bleeding from Invasion of Lymph Node Metastasis during Combination Therapy with Atezolizumab and Bevacizumab for Hepatocellular Carcinoma

Dr. Kyoko Hoshikawa (Japan)

P-156 10076

A Case of Hepatic Hemangiosarcoma Followed by Long-term Imaging

Dr. Takayuki Kogure (Japan)

P-157 10106

A Case of Hepatic Focal Nodular Hyperplasia after Liver Transplantation

Dr. Kenichi Nakamura (Japan)

P-158 10137

A Case of Scirrhous Hepatocellular Carcinoma Discovered after Combined Immunotherapy for Hepatocellular Carcinoma

Dr. Yuta Maruki (Japan)